Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.60 |
| ▸ | FLT1 | P17948 | 1/20 | 0.60 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21061612 | 0.90 | PDGFRB (0.50) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL29500857 | 0.90 | PDGFRB (0.50) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL12788081 | 0.88 | PDGFRB (0.60) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL406358 | 0.87 | MAPT (0.51) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL7641640 | 0.87 | TSHR (0.49) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL17067757 | 0.84 | TSHR (0.46) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL23861174 | 0.84 | PDGFRB (0.56) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL1028874 | 0.84 | PDGFRB (0.56) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL30443482 | 0.84 | PDGFRB (0.56) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL4993348 | 0.84 | PDGFRB (0.56) | PDGFRBFGFR1PDGFRAFLT1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058432-B2 | Method for preparing phenylalanine derivatives having quinazoline-dione skeleton and intermediates for use in the preparation of derivatives | AJINOMOTO CO., INC. (JP) | 2011-11-15 | — | — | US | disclosed |
| US-20090318688-A1 | METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-0912557-B1 | OXINDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-07-09 | — | — | EP | disclosed |
| US-6265411-B1 | ANGIOGENESIS INHIBITOR | ZENECA LIMITED (GB) | 2001-07-24 | — | — | US | disclosed |
| EP-0912557-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997042187-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318688-A1 | METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF DERIVATIVES | PAH, DDC, AADAT | PDGFRB 2716/4885FGFR1 597/4885PDGFRA 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.